当代瓣膜性心脏病的表现与管理:EURObservational研究计划瓣膜性心脏病II调查
该前瞻性调查覆盖28国222中心7247例患者,评估严重原生瓣膜病或既往瓣膜干预者的管理。原生瓣膜病患者中37.0%已干预、26.8%计划干预;无症状重度单侧左心原生瓣膜病干预决策与I类推荐一致率在主动脉瓣狭窄为79.4%、主动脉瓣反流77.6%、二尖瓣狭窄68.5%、原发性二尖瓣反流71.0%。结论认为主动脉瓣病一致性好,但二尖瓣病及转诊时机仍需改善。
要点
- 严重原生瓣膜病患者中仅37.0%已行干预、26.8%计划干预。
- 主动脉瓣狭窄干预决策与I类推荐一致率79.4%,二尖瓣狭窄仅68.5%。
- 单侧左心原生瓣膜病干预患者中47.8%为NYHA III/IV级。
核心结论
- 主动脉瓣病干预决策与I类推荐一致性较好,但二尖瓣病一致率欠佳且瓣膜干预转诊偏晚,需进一步改善指南实施。
研究设计与样本
- EURObservational Research Programme设计的前瞻性调查,2017年3个月期间在28国222中心入组7247例严重原生瓣膜病或既往瓣膜干预患者。
主要发现
- 7247例患者中位年龄71岁(IQR 62-80),1917例(26.5%)≥80岁,女性3416例(47.1%)。
- 严重原生瓣膜病5219例(72.0%),其中主动脉瓣狭窄2152例(41.2%)、主动脉瓣反流279例(5.3%)、二尖瓣狭窄234例(4.5%)、二尖瓣反流1114例(21.3%;原发性746例、继发性368例)、多发左心瓣膜病1297例(24.9%)、右心瓣膜病143例(2.7%)。
- 症状性严重单侧左心原生瓣膜病干预决策与I类推荐一致率:主动脉瓣狭窄79.4%(95%CI 77.1-81.6)、主动脉瓣反流77.6%(95%CI 69.9-84.0)、二尖瓣狭窄68.5%(95%CI 60.8-75.4)、原发性二尖瓣反流71.0%(95%CI 66.4-75.3)。
- 调查期间2150例接受瓣膜干预,其中单侧左心原生瓣膜病患者47.8%为NYHA III或IV级;主动脉瓣狭窄38.7%经导管手术,二尖瓣反流16.7%经导管手术。
关键数值与推荐
- 干预指征一致性定义:症状性患者实施或计划干预,符合2012 ESC和2014 AHA/ACC瓣膜病指南I类推荐。
- 症状性严重单侧左心原生瓣膜病与I类推荐一致率见主要发现。
临床怎么用
- 应加强二尖瓣病患者的指南导向干预决策,并关注瓣膜干预转诊时机,避免症状进展至NYHA III/IV级后才干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Valvular heart disease (VHD) is an important cause of mortality and morbidity and has been subject to important changes in management. The VHD II survey was designed by the EURObservational Research Programme of the European Society of Cardiology to analyze actual management of VHD and to compare practice with guidelines. METHODS: Patients with severe native VHD or previous valvular intervention were enrolled prospectively across 28 countries over a 3-month period in 2017. Indications for intervention were considered concordant if the intervention was performed or scheduled in symptomatic patients, corresponding to Class I recommendations specified in the 2012 European Society of Cardiology and in the 2014 American Heart Association/American College of Cardiology VHD guidelines. RESULTS: A total of 7247 patients (4483 hospitalized, 2764 outpatients) were included in 222 centers. Median age was 71 years (interquartile range, 62-80 years); 1917 patients (26.5%) were ≥80 years; and 3416 were female (47.1%). Severe native VHD was present in 5219 patients (72.0%): aortic stenosis in 2152 (41.2% of native VHD), aortic regurgitation in 279 (5.3%), mitral stenosis in 234 (4.5%), mitral regurgitation in 1114 (21.3%; primary in 746 and secondary in 368), multiple left-sided VHD in 1297 (24.9%), and right-sided VHD in 143 (2.7%). Two thousand twenty-eight patients (28.0%) had undergone previous valvular intervention. Intervention was performed in 37.0% and scheduled in 26.8% of patients with native VHD. The decision for intervention was concordant with Class I recommendations in symptomatic patients with severe single left-sided native VHD in 79.4% (95% CI, 77.1-81.6) for aortic stenosis, 77.6% (95% CI, 69.9-84.0) for aortic regurgitation, 68.5% (95% CI, 60.8-75.4) for mitral stenosis, and 71.0% (95% CI, 66.4-75.3) for primary mitral regurgitation. Valvular interventions were performed in 2150 patients during the survey; of them, 47.8% of patients with single left-sided native VHD were in New York Heart Association class III or IV. Transcatheter procedures were performed in 38.7% of patients with aortic stenosis and 16.7% of those with mitral regurgitation. CONCLUSIONS: Despite good concordance between Class I recommendations and practice in patients with aortic VHD, the suboptimal number in mitral VHD and late referral for valvular interventions suggest the need to improve further guideline implementation.
引用
- Iung B, Delgado V, Rosenhek R, et al. Contemporary Presentation and Management of Valvular Heart Disease: The EURObservational Research Programme Valvular Heart Disease II Survey. Circulation. 2019. PMID: 31510787. doi:10.1161/CIRCULATIONAHA.119.041080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。